Document Detail


Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.
MedLine Citation:
PMID:  22383630     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The aim of the present study was to investigate the effect of oral pioglitazone (PIO) on lipid metabolism, insulin resistance, inflammation, and adipokine metabolism in continuous ambulatory peritoneal dialysis (CAPD) patients.
METHODS: In this randomized crossover trial, 36 CAPD patients with serum triglyceride levels above 1.8 mmol/L were randomly assigned to receive either oral PIO 15 mg once daily or no PIO for 12 weeks. Then, after a 4-week washout, the patients were switched to the alternative regimen. The primary endpoint was change in serum triglycerides during the PIO regimen compared with no PIO. Secondary endpoints included changes in other lipid levels, homeostatic model assessment of insulin resistance (HOMA-IR), adipocytokines, and C-reactive protein (CRP).
RESULTS: All 36 CAPD patients (age: 64 ± 11 years; 33% men; 27.8% with diabetes mellitus) completed the study. Comparing patients after PIO and no PIO therapy, we found no significant differences in mean serum triglycerides (3.83 ± 1.49 mmol/L vs 3.51 ± 1.98 mmol/L, p = 0.2). However, mean high-density lipoprotein (0.94 ± 0.22 mmol/L vs 1.00 ± 0.21 mmol/L, p = 0.004) and median total adiponectin [10.34 μg/mL (range: 2.59 - 34.48 μg/mL) vs 30.44 μg/mL (3.47 - 93.41 μg/mL), p < 0.001] increased significantly. Median HOMA-IR [7.51 (1.39 - 45.23) vs 5.38 (0.97 - 14.95), p = 0.006], mean fasting blood glucose (7.31 ± 2.57 mmol/L vs 6.60 ± 2.45 mmol/L, p = 0.01), median CRP [8.78 mg/L (0.18 - 53 mg/L) vs 3.50 mg/L (0.17 - 26.30 mg/L), p = 0.005], and mean resistin (32.70 ± 17.17 ng/mL vs 28.79 ± 11.83 ng/mL, p = 0.02) all declined. The PIO was well tolerated, with only one adverse event: lower-extremity edema in a patient with low residual renal function.
CONCLUSIONS: Blood triglycerides were not altered after 12 weeks of PIO 15 mg once daily in CAPD patients, but parameters of dysmetabolism were markedly improved, including insulin resistance, inflammation, and adipokine balance, suggesting that PIO could be of value for this high-risk patient group. Larger, more definitive studies are needed to confirm these findings.
Authors:
Yun Li; Qiong-hong Xie; Huai-zhou You; Jing Tian; Chuan-ming Hao; Shan-yan Lin; Tong-ying Zhu
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-03-01
Journal Detail:
Title:  Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis     Volume:  32     ISSN:  1718-4304     ISO Abbreviation:  Perit Dial Int     Publication Date:    2012 Sep-Oct
Date Detail:
Created Date:  2012-09-19     Completed Date:  2013-03-14     Revised Date:  2013-09-03    
Medline Journal Info:
Nlm Unique ID:  8904033     Medline TA:  Perit Dial Int     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  507-15     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Huashan Hospital of Fudan University, Shanghai, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adipokines / blood
Adult
Aged
Aged, 80 and over
Biological Markers
C-Reactive Protein
Cross-Over Studies
Female
Humans
Hypoglycemic Agents / pharmacology,  therapeutic use*
Inflammation / blood,  drug therapy*,  etiology
Insulin Resistance
Lipid Metabolism Disorders / blood,  drug therapy*,  etiology
Lipids / blood
Male
Middle Aged
Peritoneal Dialysis, Continuous Ambulatory / adverse effects*
Prospective Studies
Thiazolidinediones / pharmacology,  therapeutic use*
Treatment Outcome
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Adipokines; 0/Biological Markers; 0/Hypoglycemic Agents; 0/Lipids; 0/Thiazolidinediones; 0/Triglycerides; 9007-41-4/C-Reactive Protein; X4OV71U42S/pioglitazone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Go? Expression in the Vomeronasal Organ and Olfactory Bulb of the Tammar Wallaby.
Next Document:  Two-in-one protocol: simultaneous small-pore and ultrasmall-pore peritoneal transport quantification...